Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort.
Jean-Phillippe MetgesDominique GenetDavid TougeronCatherine LigezaMichel DucreuxChristophe BorgRosine GuimbaudJean Marc PhelipLouis-Marie DourtheStefano KimPublished in: Future oncology (London, England) (2021)
Aim: We report real-world evidence with regorafenib in previously treated metastatic colorectal cancer from the French cohort of the international, prospective, observational CORRELATE study. Patients & methods: Patients receiving regorafenib according to French health authority approval were included. The primary end point was treatment-emergent adverse events. Overall survival and progression-free survival were secondary end points. Results: Two hundred and forty-two patients (61% male, median age: 66 years) were enrolled. The most common grade ≥3 drug-related treatment-emergent adverse events were hand-foot skin reaction (10.3%), asthenia/fatigue (9.9/1.2%) and hypertension (6.2%). Median overall survival and progression-free survival were 6.8 (95% CI: 6.3-7.6) and 2.8 months (95% CI: 2.6-3.0), respectively. Conclusion: The real-world safety and effectiveness data of regorafenib in metastatic colorectal cancer in France align with findings from Phase III clinical trials and the global CORRELATE population.
Keyphrases
- metastatic colorectal cancer
- free survival
- end stage renal disease
- clinical trial
- newly diagnosed
- ejection fraction
- phase iii
- chronic kidney disease
- randomized controlled trial
- peritoneal dialysis
- systematic review
- healthcare
- blood pressure
- prognostic factors
- mental health
- public health
- machine learning
- depressive symptoms
- climate change
- big data
- electronic health record
- replacement therapy
- placebo controlled